List of Excipients in Branded Drug ATOMOXETINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	ATOMOXETINE	atomoxetine hydrochloride	66993-040	DIMETHICONE
Prasco Laboratories	ATOMOXETINE	atomoxetine hydrochloride	66993-040	GELATIN
Prasco Laboratories	ATOMOXETINE	atomoxetine hydrochloride	66993-040	SODIUM LAURYL SULFATE
Prasco Laboratories	ATOMOXETINE	atomoxetine hydrochloride	66993-040	STARCH, CORN

Generic Drugs Containing ATOMOXETINE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	atomoxetine	0093-3542	AMMONIA
Teva Pharmaceuticals USA Inc	atomoxetine	0093-3542	FERROSOFERRIC OXIDE
Teva Pharmaceuticals USA Inc	atomoxetine	0093-3542	GELATIN
Teva Pharmaceuticals USA Inc	atomoxetine	0093-3542	POTASSIUM HYDROXIDE

What are the Most Frequently-Used Excipients in ATOMOXETINE?

# Of NDCs	Excipient
1	ACID RED 51
11	ALCOHOL
18	AMMONIA
1	BLUE 1

Excipient Strategy and Commercial Opportunities for Atomoxetine

Last updated: February 25, 2026

What are the key excipient considerations for atomoxetine formulations?

Atomoxetine, marketed as Strattera, is a selective norepinephrine reuptake inhibitor approved for treating ADHD. Its formulation primarily involves oral capsules containing active drug as well as excipients that influence stability, bioavailability, and patient compliance.

Current excipient profile:

• Capsule shell: Gelatin or hydroxypropyl methylcellulose (HPMC) for vegetarian options.
• Fillers: Mannitol or microcrystalline cellulose to provide tablet weight.
• Disintegrants: Cross-linked polyvinylpyrrolidone (crospovidone) facilitates capsule dissolution.
• Binders: Povidone enhances capsule integrity.
• Lubricants: Magnesium stearate improves manufacturing flow.

The choice of excipients impacts drug stability, absorption, and manufacturing efficiency.

How does excipient selection influence atomoxetine's bioavailability and stability?

Atomoxetine’s bioavailability is approximately 63%, affected by first-pass metabolism. The formulation's excipients modulate release profiles and absorption:

• Fillers and disintegrants: Control dissolution rate; faster disintegration enhances absorption.
• pH buffering agents: Can stabilize the drug in the gastrointestinal environment, affecting solubility.
• Polymers: For extended-release formulations, materials like ethylcellulose modify release kinetics.

Excipients must also maintain chemical stability, prevent moisture-induced degradation, and enhance shelf life.

What are current and emerging excipient opportunities?

Current opportunities:

• Vegetarian capsule shells: HPMC alternatives appeal to vegan markets.
• Modified release coatings: Ethylcellulose or polyvinyl acetate enable sustained release, expanding therapeutic options and market segments.
• Disintegrant innovations: Use of more efficient or plant-based disintegrants improves performance.

Emerging opportunities:

• Novel excipients: Soluble fibers or bio-compatible polymers to optimize absorption.
• Personalized excipients: Custom formulations tailored for pediatric or geriatric populations.

What are potential commercial advantages in excipient strategy?

• Market differentiation: Vegetarian capsules align with consumer preferences.
• Patent protection: Novel excipient combinations or delivery systems can extend product lifecycle.
• Manufacturing efficiency: Improved excipients reduce cost and cycle time.
• Regulatory flexibility: Well-characterized excipients ease registration hurdles.

Introducing innovative excipients or delivery systems enhances competitive positioning and can unlock new therapeutic niches.

How do regulatory considerations shape excipient choices?

Regulatory bodies enforce strict standards:

• GRAS status: Excipients must follow Generally Recognized As Safe guidelines.
• Stability data: Demonstrate chemical and physical stability over intended shelf life.
• Manufacturing consistency: Processes must meet Good Manufacturing Practices (GMP).
• Labeling and documentation: Clear listing and justification of excipients.

Regulatory approval can be streamlined using excipients with established safety profiles, but novel excipients require extensive data.

What strategies can maximize commercial opportunities with excipients?

• Formulation flexibility: Develop multiple release profiles (immediate, extended, multiparticulate) using tailored excipients.
• Market segmentation: Target niche markets (e.g., pediatric, geriatric) with specialized excipient choices.
• Partnerships: Collaborate with excipient suppliers for customized formulations.
• Intellectual property: Patent unique excipient combinations or delivery systems.

Efficient integration of excipient innovation and manufacturing can lead to sustainable competitive advantages.

Key Takeaways

• Excipient selection for atomoxetine influences drug stability, bioavailability, and patient compliance.
• Opportunities exist in vegetarian capsules, sustained-release coatings, and advanced disintegrants.
• Emerging excipients and personalized formulations can expand market reach.
• Strategic excipient choices impact regulatory approval, manufacturing costs, and IP protection.
• Differentiation through formulation innovation offers pathways to increased market share and revenue.

FAQs

1. Why are vegetarian capsules advantageous for atomoxetine?
They cater to vegan consumers, improve market appeal, and avoid allergenic gelatin components.

2. How do sustained-release excipients benefit atomoxetine formulations?
They prolong therapeutic effects, improve compliance, and expand indications.

3. What regulatory challenges exist with novel excipients?
They require comprehensive safety and stability data, prolonging approval timelines and increasing costs.

4. Can excipient modifications extend patent life?
Yes, unique formulations or delivery mechanisms involving specific excipients can create patent opportunities.

5. What key factors drive excipient innovation in ADHD medications?
Patient compliance, manufacturing efficiency, regulatory compliance, and market differentiation.

---

References

1. PDR.net. (2022). Atomoxetine hydrochloride. Retrieved from https://www.pdr.net
2. USP. (2023). United States Pharmacopeia: General Chapters and Monographs.
3. McNamara, D. et al. (2021). Advanced excipients in drug delivery systems. Journal of Pharmaceutical Sciences, 110(4), 1512-1524.
4. EMA. (2022). Guideline on the use of excipients in medicinal products. European Medicines Agency.
5. WHO. (2019). Guidelines on excipient safety and stability. World Health Organization.